GSK plc (GSK) has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has been approved for the prevention of lower respiratory tract disease (LRTD) caused by RSV in patients aged 50-59 years who are at increased risk of the disease. In the European Union (EU), there are around 65 million adults aged 50-59 years who are at increased risk for RSV disease. Out of these, an estimated 20 mil ...